SUBSCRIBE
SUBSCRIBE

Corcept Therapeutics

NEWS
Biotech Beach
The Day In Review: Immunicon Corporation Rises On AstraZeneca PLC Deal
August 7, 2006
 · 
1 min read
Biotech 2005: New Drugs Hold The Key
October 19, 2005
 · 
1 min read
Load More
JOBS
IN THE PRESS
Drug Development
Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)
June 3, 2024
 · 
3 min read
Drug Development
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)
May 28, 2024
 · 
4 min read
Business
Corcept Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 1, 2024
 · 
10 min read
Drug Development
Corcept Completes Enrollment in Phase 4 CATALYST Trial
April 29, 2024
 · 
3 min read
Business
Corcept Therapeutics to Announce First Quarter 2024 Financial Results, Provide Corporate Update and Host Conference Call
April 24, 2024
 · 
1 min read
Drug Development
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
April 22, 2024
 · 
7 min read
Drug Development
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
April 15, 2024
 · 
3 min read
Drug Development
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
April 8, 2024
 · 
4 min read
Drug Development
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
April 1, 2024
 · 
3 min read
Business
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
February 15, 2024
 · 
10 min read
Load More